Title:
ANTIBODIES BINDING CTLA4 AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/208838
Kind Code:
A1
Abstract:
An isolated monoclonal antibody that specifically binds human CTLA4, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using the anti-CTLA4 antibody or the antigen-binding portion thereof.
Inventors:
CHEN MINGJIU (CN)
XIA SHUKAI (CN)
XIA SHUKAI (CN)
Application Number:
PCT/CN2021/086484
Publication Date:
October 21, 2021
Filing Date:
April 12, 2021
Export Citation:
Assignee:
BIOSION INC (CN)
International Classes:
A61K39/395; C07K16/30; A61P31/00; A61P35/00; C12N1/21; C12N15/13
Domestic Patent References:
| WO2018183408A1 | 2018-10-04 |
Foreign References:
| CN105296433A | 2016-02-03 | |||
| CN109963588A | 2019-07-02 | |||
| CN108430499A | 2018-08-21 |
Other References:
RANDI B. GOMBOS, ET AL.: "Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody", PLOS ONE, vol. 13, no. 4, 4 April 2018 (2018-04-04), pages 1 - 28, XP055694602, DOI: 10.1371/journal.pone.0191926
Attorney, Agent or Firm:
CHENG & PENG INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: